2024
Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection
Cinco I, Napier E, Rhoades N, Davies M, Allison D, Kohama S, Bermudez L, Winthrop K, Fuss C, Spindel E, Messaoudi I. Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection. MBio 2024, 15: e00829-24. PMID: 38771046, PMCID: PMC11237422, DOI: 10.1128/mbio.00829-24.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnimalsFemaleLungMacaca mulattaMaleMicrobiotaMycobacterium Infections, NontuberculousTomography, X-Ray ComputedTranscriptomeConceptsNTM pulmonary diseaseIncreased disease severityNontuberculous mycobacteriaDisease severityBacterial DNAAged animalsAntigen-specific T cellsPulmonary diseaseAssociated with increased disease severityDysregulated macrophage responsePersistence of bacterial DNALack of animal modelsRhesus macaquesSingle-cell RNA sequencingNontuberculous mycobacterial infectionsImmune cell infiltrationRhesus macaque modelBacterial loadAged rhesus macaquesTesting novel therapeuticsRight caudal lobeLower respiratory microbiomeYears of ageMAH infectionMicrobial communities
2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchMeSH KeywordsAmikacinAnti-Bacterial AgentsAzithromycinClofazimineCystic FibrosisDrug Resistance, BacterialFemaleHumansLeprostatic AgentsLiposomesMacrolidesMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium abscessusMycobacterium Infections, NontuberculousConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapy
2021
Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States
Ku J, Siegel S, Philley J, Schipper P, Thanawala R, Hendrick M, Sigler C, Strnad L, McShane P, Griffith D, Tieu B, Caccitolo J, Fuss C, Le A, Winthrop K. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. CHEST Journal 2021, 161: 365-369. PMID: 34390707, DOI: 10.1016/j.chest.2021.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overFemaleHumansLung DiseasesMaleMiddle AgedMycobacterium Infections, NontuberculousThoracic Surgical ProceduresUnited States